streptonigrin has been researched along with Epithelial Ovarian Cancer in 1 studies
Excerpt | Relevance | Reference |
---|---|---|
"Platinum-resistant ovarian cancer is one of the most common and refractory gynecologic cancers around the world." | 2.82 | Discovery of Natural Ursane-type SENP1 Inhibitors and the Platinum Resistance Reversal Activity Against Human Ovarian Cancer Cells: A Structure-Activity Relationship Study. ( Gou, W; Guo, J; Hou, W; Li, Y; Liu, Q; Ning, H; Shang, H; Sun, X; Wei, H, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Wei, H | 1 |
Guo, J | 1 |
Sun, X | 1 |
Gou, W | 1 |
Ning, H | 1 |
Shang, H | 1 |
Liu, Q | 1 |
Hou, W | 1 |
Li, Y | 1 |
1 review available for streptonigrin and Epithelial Ovarian Cancer
Article | Year |
---|---|
Discovery of Natural Ursane-type SENP1 Inhibitors and the Platinum Resistance Reversal Activity Against Human Ovarian Cancer Cells: A Structure-Activity Relationship Study.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Cysteine Endopeptidases; Drug Resistance | 2022 |